Market Cap (In USD)
61.65 Million
Revenue (In USD)
1.75 Million
Net Income (In USD)
-21.02 Million
Avg. Volume
24.2 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.778-4.0
- PE
- -
- EPS
- -
- Beta Value
- 0.299
- ISIN
- KYG108301006
- CUSIP
- G10830100
- CIK
- 1677940
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Lan Huang Ph.D.
- Employee Count
- -
- Website
- https://www.beyondspringpharma.com
- Ipo Date
- 2017-03-09
- Details
- BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
More Stocks
-
HGLDPatagonia Gold Corp.
HGLD
-
SKCIL
-
BEAUTY
-
084650LabGenomics Co., Ltd.
084650
-
603960
-
UBX
-
VXTRFVoxtur Analytics Corp.
VXTRF
-
CDR-PCCedar Realty Trust, Inc.
CDR-PC